* patients receiving oxygen supplementation except of nasal prongs, nasal intermittent positive pressure ventilation (nippv) or high flow nasal cannula (hfnc) that are allowed to be enrolled to the study). * positive rt-pcr test more than 72 hours prior to enrolment. * onset of symptoms more than 7 days prior to enrolment. * participant using drugs that are under clinical investigation in last 30 days. * body mass index less than 19.9 or greater than 35. * comorbidities such as: other serious infections, active malignancies, autoimmune diseases, liver, kidney or heart failure; another systemic disease and / or laboratory abnormality, which, in the investigator's opinion, prevent the patient from participating in the study. * concomitant hiv, hbv or hcv infection. * pregnancy or lactation. * vaccination for any other infection in the 4 weeks prior to enrolment. * any condition that increases the risk of participating in the study, in the opinion of the investigator.

* patients receiving oxygen supplementation except of nasal prongs, nasal intermittent positive pressure ventilation (nippv) or high flow nasal cannula (hfnc) that are allowed to be enrolled to the study). * positive rt-pcr test more than 72 hours prior to enrolment. * onset of symptoms more than 7 days prior to enrolment. * participant using drugs that are under clinical investigation in last 30 days. * body mass index less than 19.9 or greater than 35. * comorbidities such as: other serious infections, active malignancies, autoimmune diseases, liver, kidney or heart failure; another systemic disease and / or laboratory abnormality, which, in the investigator's opinion, prevent the patient from participating in the study. * concomitant hiv, hbv or hcv infection. * pregnancy or lactation. * vaccination for any other infection in the 4 weeks prior to enrolment. * any condition that increases the risk of participating in the study, in the opinion of the investigator.

patients receiving oxygen supplementation except of nasal prongs, nasal intermittent positive pressure ventilation (nippv) or high flow nasal cannula (hfnc) that are allowed to be enrolled to the study). positive rt-pcr test more than 72 hours prior to enrolment. onset of symptoms more than 7 days prior to enrolment. participant using drugs that are under clinical investigation in last 30 days. body mass index less than 19.9 or greater than 35. comorbidities such as: other serious infections, active malignancies, autoimmune diseases, liver, kidney or heart failure; another systemic disease and / or laboratory abnormality, which, in the investigator's opinion, prevent the patient from participating in the study. concomitant hiv, hbv or hcv infection. pregnancy or lactation. vaccination for any other infection in the 4 weeks prior to enrolment. any condition that increases the risk of participating in the study, in the opinion of the investigator.

patients receiving oxygen supplementation except of nasal prongs, nasal intermittent positive pressure ventilation (nippv) or high flow nasal cannula (hfnc) that are allowed to be enrolled to the study). positive rt-pcr test more than 72 hours prior to enrolment. onset of symptoms more than 7 days prior to enrolment. participant using drugs that are under clinical investigation in last 30 days. body mass index less than 19.9 or greater than 35. comorbidities such as: other serious infections, active malignancies, autoimmune diseases, liver, kidney or heart failure; another systemic disease and / or laboratory abnormality, which, in the investigator's opinion, prevent the patient from participating in the study. concomitant hiv, hbv or hcv infection. pregnancy or lactation. vaccination for any other infection in the 4 weeks prior to enrolment. any condition that increases the risk of participating in the study, in the opinion of the investigator.